The developmentof a leading and proprietary pipeline is crucial forZelgen. Based on its two cutting-edge technology platforms, Zelgen has developed a solid and differential product pipeline composed of 13 new drug candidates and near 30clinical programs, which enable Zelgen covers multiple disease areas including liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, alopecia areata, ankylosing spondylitis, and atopic dermatitis et al. Its most advanced small molecule drug, Donafenib, has been proven superior to Sorafenib in a large phase 3 clinical trial for first line treatment of advanced liver cancer, which is the only TKI proven to be superior to Sorafenib in near a decade, and close to be approved for marketing by NMPA. Zelgen's Jaktinib and recombinant human thrombin as well as recombinant human TSH are also advanced to phase III clinical trials based on their successful phase 2 results. Same importantly, Zelgen has been developing its new generation of antitumor antibodies based on Gensun's superior bi/tri-specific antibody technique platforms, which confer Zelgen a global and long term competitive advantages. Zelgen has filed over 180 patent applications worldwide, of which 88patents have been issued in USA, EU, China and other countries till the end of 2020.

In addition, Zelgen has built two GMP plants for chemical tablets/capsules and recombinant proteinsin Kunshan, China. The production facilities conferthe company a great flexibility for the commercialization of its new drugs.